TREPROSTINIL
| Brand name | REMODULIN |
|---|---|
| Active ingredient | TREPROSTINIL |
| Strength | 100MG/20ML (5MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS, SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | July 2018 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 9593066 | December 2028 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.